KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) EBITDA Margin: 2010-2025

Historic EBITDA Margin for Rigel Pharmaceuticals (RIGL) over the last 11 years, with Sep 2025 value amounting to 40.91%.

  • Rigel Pharmaceuticals' EBITDA Margin rose 1550.00% to 40.91% in Q3 2025 from the same period last year, while for Sep 2025 it was 42.17%, marking a year-over-year increase of 3614.00%. This contributed to the annual value of 13.49% for FY2024, which is 3103.00% up from last year.
  • According to the latest figures from Q3 2025, Rigel Pharmaceuticals' EBITDA Margin is 40.91%, which was down 31.91% from 60.09% recorded in Q2 2025.
  • Rigel Pharmaceuticals' EBITDA Margin's 5-year high stood at 60.09% during Q2 2025, with a 5-year trough of -156.92% in Q1 2022.
  • Moreover, its 3-year median value for EBITDA Margin was 5.49% (2023), whereas its average is 7.10%.
  • The largest annual percentage gain for Rigel Pharmaceuticals' EBITDA Margin in the last 5 years was 10,900bps (2022), contrasted with its biggest fall of 20,846bps (2022).
  • Quarterly analysis of 5 years shows Rigel Pharmaceuticals' EBITDA Margin stood at -104.94% in 2021, then soared by 10,900bps to 4.05% in 2022, then skyrocketed by 144bps to 5.49% in 2023, then skyrocketed by 2,342bps to 28.92% in 2024, then soared by 1,550bps to 40.91% in 2025.
  • Its last three reported values are 40.91% in Q3 2025, 60.09% for Q2 2025, and 23.95% during Q1 2025.